Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), A P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors.

Trial Profile

Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), A P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2017

At a glance

  • Drugs Tariquidar (Primary) ; Docetaxel; Doxorubicin; Filgrastim; Vinorelbine
  • Indications Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Liver cancer; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top